Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition

被引:19
|
作者
Jin, Hyeon-Ok [1 ]
Lee, Yun-Han [2 ]
Park, Jin-Ah [1 ]
Kim, Jin-Hee [1 ]
Hong, Sung-Eun [3 ]
Kim, Hyun-Ah [4 ]
Kim, Eun-Kyu [4 ]
Noh, Woo Chul [4 ]
Kim, Byung-Hak [5 ]
Ye, Sang-Kyu [5 ]
Chang, Yoon Hwan [6 ]
Hong, Seok-Il [6 ]
Hong, Young-Joon [6 ]
Park, In-Chul [3 ]
Lee, Jin Kyung [1 ]
机构
[1] Korea Inst Radiol & Med Sci, KIRAMS Radiat Blood Specimen Biobank, Seoul 139709, South Korea
[2] Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul 120752, South Korea
[3] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea
[4] Korea Inst Radiol & Med Sci, Dept Surg, Korea Canc Ctr Hosp, Seoul 139706, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea
[6] Korea Inst Radiol & Med Sci, Dept Lab Med, Korea Canc Ctr Hosp, Seoul 139709, South Korea
关键词
Akt; Bim; CHOP; mTOR; PI3K; Stat3; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; SIGNAL TRANSDUCER; CANCER; NVP-BEZ235; ACTIVATION; APOPTOSIS; PATHWAY; LEADS; PTEN;
D O I
10.1016/j.bbrc.2014.01.086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K/Akt/mTOR axis in lung cancer is frequently activated and implicated in tumorigenesis. Specific targeting of this pathway is therefore an attractive therapeutic approach for lung cancer. However, non-small cell lung cancer cells are resistant to BEZ235, a dual inhibitor of PI3K and mTOR. Interestingly, blockage of Stat3 with a selective inhibitor, S3I-201, or siRNA dramatically sensitized the BEZ235-induced cell death, as evident from increased PARP cleavage. Furthermore, inhibition of Stat3 led to enhancement of cell death induced by LY294002, a PI3K inhibitor. Treatment of cells with a combination of BEZ235 and S3I-201 significantly induced the proapoptotic transcription factor, CHOP, and its targets, Bim and DR4. Knockdown of CHOP or Bim suppressed cell death stimulated by the combination treatment, implicating the involvement of these BEZ235/S3I-201-induced factors in pronounced cell death. Moreover, the BEZ235/S3I-201 combination enhanced TRAIL-induced cell death. Our results collectively suggest that blockage of Stat3 presents an effective strategy to overcome resistance to PI3K/Akt/mTOR inhibition. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:502 / 508
页数:7
相关论文
共 50 条
  • [31] Determinants of acquired resistance to PI3K/mTOR inhibition in cells refractory to EGFR inhibition.
    Koh, King Xin
    Bhattacharya, Bhaskar
    Loh, Joanne
    Ng, Hong Kiat
    Soo, Ross
    Iacopetta, Barry
    Soong, Richie
    CANCER RESEARCH, 2013, 73 (08)
  • [32] Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
    Bhatt, Aadra P.
    Bhende, Prasanna M.
    Sin, Sang-Hoon
    Roy, Debasmita
    Dittmer, Dirk P.
    Damania, Blossom
    BLOOD, 2010, 115 (22) : 4455 - 4463
  • [33] Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
    Moon, Seo Yun
    Lee, Heejin
    Kim, Seoree
    Hong, Ji Hyung
    Chun, Sang Hoon
    Lee, Hee Yeon
    Kang, Keunsoo
    Kim, Ho Shik
    Won, Hye Sung
    Ko, Yoon Ho
    BMC CANCER, 2021, 21 (01)
  • [34] Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
    Seo Yun Moon
    Heejin Lee
    Seoree Kim
    Ji Hyung Hong
    Sang Hoon Chun
    Hee Yeon Lee
    Keunsoo Kang
    Ho Shik Kim
    Hye Sung Won
    Yoon Ho Ko
    BMC Cancer, 21
  • [35] In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
    Pyuen, Alex A.
    Thamm, Douglas H.
    CANCER RESEARCH, 2016, 76
  • [36] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [37] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [38] In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
    Pyuen, Alex A.
    Meuten, Travis
    Rose, Barbara J.
    Thamm, Douglas H.
    PLOS ONE, 2018, 13 (07):
  • [39] Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
    Huang, Shile
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 967 - 970
  • [40] PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients
    Heavey, Susan
    Toomey, Sinead
    Carr, Aoife
    Cuffe, Sinead
    Finn, Stephen
    Hennessy, Bryan
    Crown, John
    Barr, Martin
    O'Byrne, Kenneth
    Gately, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)